Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2026

Conditions

Colorectal CancerImmunotherapyRadiotherapyTargeted TherapyLiver Metastasis

Interventions

DRUG

Immunotherapy (Sintilimab)

Sintilimab

DRUG

Targeted Therapy Agent (Fruquintinib)

Fruquintinib

RADIATION

Radiotherapy (SBRT and LDRT)

SBRT and LDRT

Trial Locations (1)

RECRUITING

Jinbo Yue, Jinan

All Listed Sponsors

lead

Shandong Cancer Hospital and Institute

OTHER